PASG - Spring Meeting. Pharmaceutical Analysis - Future Challenges and Opportunities
Hilton Milton Keynes
10th - 11th May 2010



The theme of the conference is Future Challenges and Opportunities in the field of Pharmaceutical Analysis, and promises to be a highly topical and focussed meeting with presentations driven by current practitioners in the field. In particular, the conference will focus on the themes of Quality by Design, Lean practice, Dissolution and Novel Technology. There will be plenty of opportunity to interact with the speakers both in the round table discussions at the end of each session, and informally during the two days of the conference. The conference promises to be a highly enjoyable and interactive survey of the state of current and potential future practice, with plenty of opportunity for networking with your peers.

Date: 10th and 11th May 2010
Location: Hilton Milton Keynes

Application and Fees: 2 days with accommodation & dinner on the Monday night 490
1 day with NO accommodation 220
2 days with NO accommodation 400

If accommodation is required on Sunday please contact the hotel directly.

Early Bird deadline has now passed.

Call for Poster Presentations - If you wish to present a poster, please apply be submitting an abstract to PASG@mmsconferencing.com

For Further Information:

Please contact Samantha DeMello.


Quality by Design

  • QbD approaches and case studies, David Holt, AstraZeneca
  • Real Time Release, Stuart Goodall, Pfizer
  • Process analytical technology for real time release testing, TBC, BMS
  • A QbD approach to extractables and leachables,Andrew Fielden, AstraZeneca
  • A QbD approach to dry powder inhaler fine particle dose speciation, Alan Silcock, Pfizer
Dissolution

  • Biorelevant dissolution,Claudia Neri, Merck
  • Dissolution QbD,Kevin Ryan, Pfizer
  • Dissolution surrogates - TIM TNO,Nick Stainforth, AstraZeneca
  • Advanced dissolution testing, Stephen Wren, AstraZeneca
Lean & Continuous Improvement

  • Overview session of Lean and C and I, TBC
  • Centralised stability testing,TBC, GSK
  • Accelerated stability assessment program, Garry Scrivens, Pfizer
Novel technology

  • NMR for PGIs, Andrew Phillips, AstraZeneca
  • Hyperspectral imaging,TBC
  • Pairwise distribution factors for amorphous materials, Helen Blade, AstraZeneca
  • Novel sample preparation for extractables and leachables, Shane Smith, GSK